Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Total-Body PET with [18F]Flutemetamol in Patients with Post-COVID Syndrome (Long COVID)

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is being done in post-COVID syndrome (also called long COVID), a condition in which symptoms continue after a COVID-19 infection. The study uses flutemetamol (18F), a radioactive tracer given into a vein, to help look for tiny blood clots that contain a protein called amyloid. The purpose of the study is to see whether these amyloid-containing microclots can be seen and measured in people with post-COVID syndrome compared with control participants.

During the study, participants receive flutemetamol (18F) and then undergo a PET scan, which is an imaging test that shows where the tracer goes in the body. Some participants may also have a MRI scan, which uses magnetic fields to create pictures of the brain. Blood samples and symptom questionnaires are also used to gather more information about the amount of microclots and the presence and severity of symptoms.

The study is expected to run over several months. It focuses on whether this imaging method can show differences in amyloid-containing microclots between people with post-COVID syndrome and controls, and whether these findings relate to symptoms and brain scan results.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Study entry and first trial visit

    After you join the study, you take part in the first trial visit. During this stage, the study uses flutemetamol (18f), which is given as an intravenous dose. This means it is put into a vein through a needle. The source data does not give a dose amount.

    The trial uses a total-body dynamic pet scan. pet means positron emission tomography, which is a scan that shows where the study drug is found in your body. The scan is used to measure how much of the study drug binds in different parts of the body.

  2. Step 2

    Imaging and measurement stage

    After the injection, you undergo the total-body dynamic pet scan. This scan is used to look for and measure amyloid-containing microclots. Amyloid is a type of protein, and microclots are very small blood clots.

    The scan measures how the study drug behaves in your body over time. The main measurements are reported as volume of distribution or non-displaceable binding potential. These are technical ways of describing how much of the study drug is held in body tissues.

  3. Step 3

    Blood testing stage

    You provide blood samples so the study can measure the amount of amyloid-containing microclots in your blood. The study records both the size and the quantity of these microclots.

    No blood test timing, number of samples, or duration of collection is specified in the source data.

  4. Step 4

    Questionnaire stage

    You complete questionnaires about the presence and severity of your post-covid symptoms. These questionnaires ask how symptoms are affecting you and how severe they are.

    The source data does not provide the number of questionnaires, the exact timing, or how long this stage lasts.

  5. Step 5

    Mri stage

    You undergo mri, which means magnetic resonance imaging. This is a scan used to look at the structure and function of the brain.

    The study uses the mri results to measure brain structure and function. The source data does not state the number of scans or the timing of this stage.

  6. Step 6

    Study completion

    After the planned scan, blood testing, questionnaires, and mri are finished, your participation in the trial ends.

    The source data gives the estimated study period as starting on 2026-03-02 and ending on 2026-12-31.

Who can join the trial?

5 criteria

  • The person must have had symptomatic COVID-19, meaning they had symptoms during the infection, and the infection must have been confirmed by a positive PCR test for SARS-CoV-2 (a laboratory test that detects the virus that causes COVID-19).
  • The person must be at least 12 months past the time they were diagnosed with COVID-19.
  • The person must be between 40 and 65 years old.
  • The person must have enough command of the Dutch language to understand the study procedures and instructions.
  • The person must be able to undergo the PET scan procedures, where PET stands for positron emission tomography, a type of imaging test that shows activity inside the body.

Who cannot join the trial?

4 criteria

  • Having another medical condition linked to amyloid formation (a buildup of an abnormal protein called amyloid), such as diabetes, rheumatoid arthritis (a long-term disease that causes joint inflammation), or neurodegenerative disorders (diseases that damage the brain or nerves, such as some forms of dementia).
  • Being unable to have the scanning tests because of claustrophobia (fear of enclosed spaces), severe back pain, or trypanophobia (fear of needles).
  • Using anti-coagulant drugs (medicines that reduce blood clotting, often called blood thinners).
  • Being a female who can become pregnant and who is not surgically sterile (permanently unable to have children after surgery), is not avoiding sexual activity, or is not using a reliable method of contraception (a dependable way to prevent pregnancy).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

  • Verified

    Amsterdam UMC

    The NetherlandsAmsterdam, The Netherlands

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Flutemetamol (18F) is a PET imaging tracer used in this study to help doctors see and measure amyloid-containing microclots in the body. It is given through a vein and works as a special marker that can attach to certain targets in the blood vessels and tissues, allowing the scan to show where these microclots may be present and how much there is. This helps researchers compare post-COVID patients with healthy controls.

What is already known about the treatment

Flutemetamol (18F) - Flutemetamol (18F) is given by intravenous injection, usually as a single dose into a vein, and then it is scanned with PET imaging to show where it collects in the body. It is a radioactive tracer used in medical imaging, not a treatment, and it is well known in medical literature as an approved brain imaging agent for detecting amyloid deposits. Its main use is to help doctors study and assess diseases linked to amyloid buildup, especially certain memory and brain disorders, and in this trial it is being used to look for amyloid-containing microclots in post-COVID syndrome. At the molecular level, it binds to amyloid protein structures, and because it carries fluorine-18, it emits a signal that can be detected by PET; it is classified as a diagnostic radiopharmaceutical and PET imaging agent.

Investigated diseases

Post-COVID-19 syndrome - A condition that develops after a person has had COVID-19 and continues for weeks or months beyond the initial infection. It can involve a wide range of ongoing symptoms that may change over time, with some symptoms gradually improving while others persist or come and go.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2025-522348-42-00Estimated enrolment65 patientsSponsorAmsterdam UMC Stichting

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).